Fast-Track Vaccine Development and Market Approval During the Corona Pandemic

Infection and Immunity
Online live-streamed seminar - Link below
Prof. dr. Ton de Boer
  • To watch back the seminar, click on this link
  • You can no longer register for this seminar, but you can still watch it back. 

Within one year effective vaccines were developed and approved by medicine authorities during the corona pandemic. Normally the development of a “new” vaccine takes 4-10 years and the approval process for market entry 1,5 years. Intense collaboration between the different stakeholders was essential  for this accomplishment.  Using existing techniques (like used for the mRNA-vaccines), parallel studies, instruments to speed up the approval process (e.g. rolling review), conditional marketing approval and risk management plans were key in the fast-track process. In my presentation I will look back and what we can expect in the future to remain protected from the coronavirus.

About the speaker

Prof. Anthonius de Boer, MD, PhD was trained for three years in Internal Medicine followed by a PhD research period in clinical pharmacology. After his PhD graduation in 1990 he was appointed as assistant professor in Clinical Epidemiology followed by an associate professorship of pharmacotherapy. In 1994 he was registered as Epidemiologist and in 1996 as Clinical Pharmacologist.

He was appointed in 2001 as professor of pharmacotherapy and director of the Pharmacy School. From 2007-2015 he was the head of the Department of Pharmaceutical Sciences, Utrecht University, from 2002-2014 he was a member of the Central Ethics Committee of the Netherlands and from 2014-2017 he was the chairman of the Drug Committee of the National Health Care Institute (ZIN). He is the chairman of the Board of the National Institute of Post-Academic Education of Pharmacy, chairman of the Certification Committee of the Dutch Society of Clinical Pharmacology and Biopharmacy,  member of the Programme “Goed Gebruik Geneesmiddelen” of ZonMw and European Senior Editor of the British Journal of Clinical Pharmacology. In 2017 he started as the chairman of the Medicines Evaluation Board of the Netherlands. He is involved in teaching of students of the bachelor Pharmacy, College of Pharmaceutical Sciences, research master Drug Innovation, and master of Pharmacy. His research interests are directed on methods of pharmacoepidemiology, pharmacogenetics in the field of cardiovascular diseases. Large prescription databases linked to medical information are used. The number of peer reviewed, both international and national, papers is appr. 500. His H-factor is 50 (Web of Science).

Add to your calendar